ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 228 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,561 | -4.7% | 37,971 | +8.2% | 0.01% | 0.0% |
| Q1 2024 | $1,638 | -1.7% | 35,093 | +0.7% | 0.01% | -12.5% |
| Q4 2023 | $1,667 | +57.4% | 34,853 | +17.3% | 0.01% | +33.3% |
| Q3 2023 | $1,059 | -22.3% | 29,703 | +0.5% | 0.01% | -14.3% |
| Q2 2023 | $1,363 | +16.4% | 29,553 | +1.2% | 0.01% | 0.0% |
| Q1 2023 | $1,171 | -12.8% | 29,193 | +0.7% | 0.01% | -12.5% |
| Q4 2022 | $1,343 | -99.9% | 28,983 | +1.3% | 0.01% | 0.0% |
| Q3 2022 | $1,185,000 | -29.7% | 28,613 | +1.3% | 0.01% | -27.3% |
| Q2 2022 | $1,685,000 | -3.3% | 28,243 | +17.7% | 0.01% | +10.0% |
| Q1 2022 | $1,742,000 | -12.2% | 23,989 | +1.6% | 0.01% | 0.0% |
| Q4 2021 | $1,985,000 | -5.2% | 23,609 | +1.7% | 0.01% | -16.7% |
| Q3 2021 | $2,093,000 | -2.2% | 23,209 | +3.5% | 0.01% | 0.0% |
| Q2 2021 | $2,139,000 | – | 22,430 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
| Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
| Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
| AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
| SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
| EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
| FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
| HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
| Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |